WO1996013263A3 - Methods of treatment of viral disease with inhibitors of sphingolipid biosynthesis - Google Patents

Methods of treatment of viral disease with inhibitors of sphingolipid biosynthesis Download PDF

Info

Publication number
WO1996013263A3
WO1996013263A3 PCT/US1995/014070 US9514070W WO9613263A3 WO 1996013263 A3 WO1996013263 A3 WO 1996013263A3 US 9514070 W US9514070 W US 9514070W WO 9613263 A3 WO9613263 A3 WO 9613263A3
Authority
WO
WIPO (PCT)
Prior art keywords
sphingolipid biosynthesis
inhibitors
treatment
methods
viral disease
Prior art date
Application number
PCT/US1995/014070
Other languages
French (fr)
Other versions
WO1996013263A2 (en
Inventor
Meir Lev
K Soma Sundaram
Yaffa Mizrachi
Arye Rubinstein
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of WO1996013263A2 publication Critical patent/WO1996013263A2/en
Publication of WO1996013263A3 publication Critical patent/WO1996013263A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a novel method of inhibition of virus replication. In particular, the present invention is directed to the use of an inhibitor of sphingolipid biosynthesis for the treatment or prevention of infection caused by enveloped viruses, including HIV. L-cycloserine is the preferred inhibitor of sphingolipid biosynthesis. Pharmaceutical compositions comprising inhibitors of sphingolipid biosynthesis, including L-cycloserines, are also provided.
PCT/US1995/014070 1994-11-01 1995-10-30 Methods of treatment of viral disease with inhibitors of sphingolipid biosynthesis WO1996013263A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33296994A 1994-11-01 1994-11-01
US08/332,969 1994-11-01

Publications (2)

Publication Number Publication Date
WO1996013263A2 WO1996013263A2 (en) 1996-05-09
WO1996013263A3 true WO1996013263A3 (en) 1996-06-13

Family

ID=23300674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/014070 WO1996013263A2 (en) 1994-11-01 1995-10-30 Methods of treatment of viral disease with inhibitors of sphingolipid biosynthesis

Country Status (1)

Country Link
WO (1) WO1996013263A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0007491A (en) * 1999-01-13 2001-11-20 Jomaa Pharmaka Gmbh Use of 3-isoxazolidinones and hydroxylamic acids to treat infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C.M.BATES: "HIV medicine: drug side effects and interactions", POSTGRADUATE MEDICAL JOURNAL, vol. 72, no. 843, pages 30 - 36 *
N.G. KASPARYAN: "GLYCOSPHINGOLIPID METABOLISM AND SHEDDING IN NON-TRANSFORMED AND MURINE SARCOMA VIRUS TRANSFORMED METASTATIC VARIANT CELLS", DIALOG(R)FILE 35: DISSERTATION ABSTRACTS ONLINE, ABSTRACT 0978983 *
Y.MIZRACHI ET AL.: "L-Cycloserine, an Inhibitor of Sphingolipid Biosynthesis, Inhibits HIV-1 Cytopathic Effects, Replication, and Infectivity", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, vol. 11, no. 2, 1 February 1996 (1996-02-01), pages 137 - 141 *

Also Published As

Publication number Publication date
WO1996013263A2 (en) 1996-05-09

Similar Documents

Publication Publication Date Title
WO2001090121A3 (en) Methods and compositions for treating hepatitis c virus
EP1340744A3 (en) Hiv protease inhibitors
WO2003026589A3 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
UA66767C2 (en) Serine proteases inhibitors, pharmaceutical composition, a method for inhibitining activity and a method for treatment or prevention of viral infection of hepatitis c
WO1996006620A3 (en) Lipid analogs for treating viral infections
WO2001060315A3 (en) Method for the treatment or prevention of flavivirus infections using nucleoside analogues
CA2163456A1 (en) New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
NZ515392A (en) Respiratory syncytial virus replication inhibitors
CA2075173A1 (en) Compounds and methods for inhibition of hiv and related viruses
MX9603909A (en) Sulphonamide derivatives as aspartyl protease inhibitors.
MXPA03002022A (en) Multivalent neuraminidase inhibitor conjugates.
WO1997020554B1 (en) Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc
BR9711095A (en) Substituted cyclopentane compound, composition and method for inhibiting influenza virus neuraminidase and method for treating influenza virus infection
MX9207449A (en) INHIBITORS OF THE PROTEOLYTIC ENZYME DERIVED FROM SACARINE.
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
BG102106A (en) Phermaceutical composition containing proteinase inhibitor and monoglyceride
NZ505894A (en) Methylenebisbenzaldehyde derivatives, methylidynetrisphenol derivative and pharmaceuticals thereof; useful for treating or preventing pneumovirus infection and associated diseases
ZA991029B (en) Composition and methods for treatment of hiv infections.
WO1996013263A3 (en) Methods of treatment of viral disease with inhibitors of sphingolipid biosynthesis
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
WO1996000068A3 (en) Combination therapy for hiv infection
GEP20022764B (en) HIV Protease Inhibitors, Pharmaceutical Compositions and Methods for Inhibiting HIV Protease
WO1998009951A3 (en) Intermediates for making hiv-protease inhibitors and methods of making hiv-protease inhibitors
AU630249B2 (en) Prevention of glycoprotein enveloped virus infectivity by quinolyloxazole-2-ones
WO2003093415A3 (en) Methods useful in treatment and prevention of hiv infection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase